<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="33558">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02034019</url>
  </required_header>
  <id_info>
    <org_study_id>OTX-13-002</org_study_id>
    <nct_id>NCT02034019</nct_id>
  </id_info>
  <brief_title>Phase 3 Study Evaluating Safety and Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ocular Therapeutix, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ocular Therapeutix, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of OTX-DP as a sustained release drug (dexamethasone)
      depot when placed in the canaliculus of the eyelid for  the treatment of post-surgical
      inflammation and pain in subjects who have undergone cataract extraction with intra-ocular
      lens implantation.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Absence of cells in anterior chamber of the study eye</measure>
    <time_frame>Day 14</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cells in the anterior chamber in the study eye</measure>
    <time_frame>Days 2, 4, 8, 30</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain in the study eye</measure>
    <time_frame>Days 2, 4, 14, 30</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Post Ocular Surgical Inflammation and Pain</condition>
  <arm_group>
    <arm_group_label>OTX-DP (Dexamethasone Punctum Plug)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Resorbable hydrogel drug delivery vehicle containing dexamethasone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PVPP (Placebo Punctum Plug)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Resorbable hydrogel drug delivery vehicle containing no drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <arm_group_label>OTX-DP (Dexamethasone Punctum Plug)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Punctum Plug</intervention_name>
    <arm_group_label>OTX-DP (Dexamethasone Punctum Plug)</arm_group_label>
    <arm_group_label>PVPP (Placebo Punctum Plug)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has a cataract and is expected to undergo clear corneal cataract surgery with
             phacoemulsification and implantation of a posterior chamber intraocular lens

          -  Has a potential post-operative pinhole corrected Snellen VA of at least 20/200 or
             better in both eyes

        Exclusion Criteria:

          -  Any intraocular inflammation in the study eye present during the screening slit lamp
             examination

          -  Score greater than &quot;0&quot; on the Ocular Pain Assessment in the study eye at Screening

          -  Any intraocular inflammation in the study eye present during the screening slit lamp
             examination
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deepa Mulani</last_name>
    <role>Study Director</role>
    <affiliation>Sponsor GmbH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Deepa Mulani</last_name>
    <phone>781-357-4023</phone>
    <email>dmulani@ocutx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stephen Curwen</last_name>
    <phone>781-357-4009</phone>
    <email>scurwen@ocutx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Texan Eye / Keystone Research, Ltd.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tom R Walters, MD</last_name>
      <phone>512-327-7000</phone>
    </contact>
    <investigator>
      <last_name>Tom R Walters, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 9, 2014</lastchanged_date>
  <firstreceived_date>January 9, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
